Suzanne Feigofsky, MD
Cardiovascular Disease · West Des Moines, IANPI 1598760753
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Medtronic at 51.2% of the total. 2025 is the largest year on record at $12,348, 3.0 times the $4,134 reported in 2019. Among cardiovascular disease clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $211.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$30K
- Abbott$17K
- Boston Scientific$8K
- Lundbeck LLC$4K
- Astellas Pharma US Inc$130
- Novartis$124
- plus $279 from 6 others
What the payments were for
- Consulting fees$6,55011%
- Speaking & faculty fees$25,08843%
- Travel & lodging$15,17526%
- Food & beverage$11,58720%
- Education$1300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 165 | $29,951 |
| Abbott | 81 | $16,687 |
| Boston Scientific | 9 | $7,773 |
| Lundbeck LLC | 3 | $3,587 |
| Astellas Pharma US Inc | 2 | $130 |
| Novartis | 7 | $124 |
| Johnson & Johnson | 2 | $117 |
| Pfizer | 1 | $58 |
| Boehringer Ingelheim | 3 | $50 |
| Amgen | 2 | $33 |
| Merck | 1 | $13 |
| Lemaitre Vascular, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$9,310
- GENERAL - THERAPIES$7,663
- NORTHERA$3,587
- ENSITE PRECISION$3,011
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$1,305
- Micra$1,181
- Arctic Front$481
- AVEIR$399
- AURORA EV-ICD MRI SURESCAN$326
- ALLURE$250
- COBALT DR MRI SURESCAN$180
- Confirm Rx$135
- Allure Quadra RF CRT Pacemaker$122
- ENSITE$119
- XARELTO$101
How this compares
$58,530 in reported general payments places this provider in the 95th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 241 | $183,545 |
| EntrestoSacubitril/Valsartan | 107 | $69,149 |
| XareltoRivaroxaban | 36 | $39,251 |
| Repatha SureclickEvolocumab | 41 | $28,425 |
| JardianceEmpagliflozin | 34 | $20,200 |
| BrilintaTicagrelor | 20 | $10,030 |
| Praluent PenAlirocumab | 17 | $7,861 |
| VerquvoVericiguat | 11 | $6,930 |
| Flecainide Acetate | 183 | $4,258 |
| Metoprolol Succinate | 400 | $3,808 |
| Midodrine Hcl | 65 | $3,349 |
| Bumetanide | 90 | $2,649 |
| Dofetilide | 19 | $2,418 |
| Amiodarone Hcl | 157 | $2,038 |
| SotalolSotalol Hcl | 81 | $1,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $183,545241 claims |
| NovartisEntresto | $124 | $69,149107 claims |
| Johnson & JohnsonXarelto | $117 | $39,25136 claims |
| Boehringer IngelheimJardiance | $50 | $20,20034 claims |
| MerckVerquvo | $13 | $6,93011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in West Des Moines
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Robert PaulWest Des Moines$9K
- Lucas GrobenWest Des Moines$6K
- Krishna Theja ReddyWest Des Moines$5K
- Randolph RoughWest Des Moines$3K
- Paul WesleyWest Des Moines$2K
- Brian OlshanskyIowa City$219K
- Gursukhman Deep SidhuDavenport$60K
- Tyler RasmussenCedar Rapids$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.